A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: Tumor-specific immune responses are associated with improved survival

Clinical Cancer Research

Volumn 16, Issue 22, 2010, Pages 5548-5556

  Barth Jr , Richard J ^a   Fisher, Dawn A ^a   Wallace, Paul K ^a   Channon, Jacqueline Y ^a   Noelle, Randolph J ^a   Gui, Jiang ^a   Ernstoff, Marc S ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; CD83 ANTIGEN; CD86 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; KEYHOLE LIMPET HEMOCYANIN; UNCLASSIFIED DRUG; VACMUNE;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; CANCER VACCINES; CD40 LIGAND; COLORECTAL NEOPLASMS; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 78349241798     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2138     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Fong Y, Fortner J, Sun R, Brennan M, Blumgart M. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-18.
3. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. Cancer 1996;77:1254-62.
4. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976-82.
5. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery vs surgery alone for resectable liver metastases from colorectal cancer: a randomised controlled trial. Lancet 2008;371:1007-16.
6. Vermorken JB, Claessen A, Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet 1999;353:345-50.
7. Harris J, Ryan L, Hoover H, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: ECOG study E5283. J Clin Oncol 2000;18:148-57.
8. Lambert L, Gibson G, Maloney M, Barth R. Equipotent generation of protective anti-tumor immunity by various methods of dendritic cell loading with whole cell tumor antigens. J Immunother 2000;24:232-6.
9. Engell-Noerregaard L, Hansen T, Andersen M, Straten P, Svane I. Review of clinical studies on dendritic cell based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009;58:1-14.
10. Lambert L, Gibson G, Maloney M, Durell B, Noelle R, Barth R. Intranodal immunization with tumor lysate pulsed dendritic cells enhances protective anti-tumor immunity. Cancer Res 2001;61:641-6.
11. + T-cell function in melanoma patients. J Clin Oncol 2003;21:3826-35.
12. Mackey M, Gunn J, Ting P, et al. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand CD154. Cancer Res 1997;57:2569-74.
13. Elgueta R, Benson M, de Vries V, Wasiuk A, Guo Y, Noelle R. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152-72.
14. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999;162:168-75.
15. Givan AL, Fisher J, Waugh M, Ernstoff M, Wallace P. A flow cytometric to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods 1999;230:99-112.
16. Bercovici N, Givan A, Waugh M, et al. Multiparameter precursor analysis of T cell responses to antigen. J Immunol Methods 2003;276:5-17.
17. Nagorsen D, Keilholz U, Rivoltini L, et al. Natural T cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu and CEA in patients with colorectal cancer. Cancer Res 2000;60:4850-4.
18. Cella M, Scheidegger D, Palmer-Lehman K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of IL-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996;184:747-52.
19. Lapointe R, Toso J, Butts C, Young H, Hwu P. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen specific T lymphocytes. Eur J Immunol 2000;30:3291-8.
20. Butterfield L, Gooding W, Whiteside T. Development of a potency assay for human dendritic cells: IL-12 p70 production. J Immunother 2008;31:89-100.
21. Chang A, Redman B, Whitfield J, et al. A phase I trial of tumor lysate pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002;8:1021-32.
22. Tamir A, Basaglia E, Kagahzian A, et al. Induction of tumor specific T cell responses by vaccination with tumor lysate loaded dendritic cells in colorectal cancer patients. Cancer Immunol Immunother 2007;56:2003-16.
23. Mazzolini G, Alfaro C, Sangro B, et al. Intratumoral injection of dendritic cells engineered to secrete IL-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 2005;23:999-1010.
24. Morse MA, Deng Y, Coleman D, et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5:1331-8.
25. Itoh T, Ueda Y, Kawashima I, et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen. Cancer Immunol Immunother 2002;51:99-106.
26. Fong L, Hou Y, Rivas A, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci U S A 2001;98:8809-14.
27. Nagorsen D, Thiel E. Clinical and immunological responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 2006;12:3064-9.
28. Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
29. Dudley M, Wunderlich J, Yang J, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
30. Morse M, Nair S, Mosca P, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003;21:341-9.
31. Dunn G, Old L, Schreiber R. The three Es of cancer immunoediting. Ann Rev Immunol 2004;22:329-60.